Tag Archives: ip

Common Citation Document Launched By Trilateral Patent Offices

Posted on November 17, 2011 by Warren Woessner

This posting came with a set of presentation slides which you can find at the end of the post. The Industry Trilateral (of which IPO is a member) initially proposed a Common Citation Document (CCD).  In response, the Trilateral have … Continue reading →

Posted in Int'l Practice and Policy | Tagged , , , , , , , | Leave a comment

Excerpts From Amicus Briefs Supporting Prometheus

Posted on November 11, 2011 by Warren Woessner

This intriguing compilation “Excerpts From 15 AMICI Briefs Supporting Respondent Prometheus: Mayo Collaborative Services v. Prometheus Laboratories, Inc.,” was sent to me by Mark Corallo of Corallo Media Strategies, Inc., Alexandria, VA. UNH Law used to be Franklin Pierce Law … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

EPO Ruling On Inventiveness Of Drug Polymorphs

Posted on November 5, 2011 by Warren Woessner

Thank you to Dr. Stefan Danner, a German and European Patent Attorney at DHS Patentanwaltsgesellschaft mbH in Munich for letting us post the current issue of the biotech IP newsletter dealing with the recent EPO decision concerning the patentability of … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , , , , , , | Leave a comment

Mayo’s Brief Goes Back To A (Non-Precedential) Future

Posted on November 3, 2011 by Warren Woessner

You all may be suffering from Prometheus v. Mayo fatigue by now, but this remains the most important IP case before the Supreme Court, and may well alter the course of life sciences patenting for the foreseeable future. I know … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 1 Comment